RedMedEd

RedMedEd

Overview

At RedMedEd, increasing clinician competence and improving patient care is the name of the game.

With a track record of excellence in CME and a wide range of innovative gamification and interactive learning designs, the RedMedEd team delivers initiatives that are fresh, rigorous, engaging, and memorable.

When CME is done well, clinicians learn and patients win.


A Clinical Guide to Diagnosing and Treating Lyme Disease and Other Tick-Borne Illnesses

Overview Establishing a Lyme disease diagnosis remains a considerable challenge, as many symptoms are nonspecific and there are currently no definitive diagnostic tests available. This represents a significant clinical problem, as the number of Lyme disease cases in the U.S. is steadily increasing. This activity presents and discusses recent advances in the management of Lyme disease and other ...
Jointly provided by Postgraduate Institute for Medicine and RedMedEd, in collaboration with the State of Delaware and Global Lyme Alliance.

CLL Patient Exam in the Era of Targeted Therapies: Workup, Prognosis, Treatment, and Monitoring

The rapid evolution of treatment advances in chronic lymphocytic leukemia (CLL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of novel targeted biologic agents in CLL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection (including drug combinations and sequencing ther...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

Current Obstacles in Myeloma Management: Debating the Evidence

ACTIVITY DESCRIPTION The clinical multiple myeloma arena has seen significant advances in treatment, diagnosis, imaging, disease monitoring, and supportive care. The approval of several new agents has led to expanded criteria for earlier-stage diagnosis in some higher-risk patients with smoldering multiple myeloma (SMM), though questions remain regarding optimal treatment of other SMM patients....
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Eradication of Minimal Residual Disease in Multiple Myeloma: The Role and Timing of ASCT

Advances in multiple myeloma (MM) management have equipped oncology health care providers with the tools and strategies for achieving treatment responses in up to 100% of patients, with as many as 80% reaching a complete response (CR). However, achieving a CR does not always predict long-term survival, and most patients ultimately relapse as a result of the persistence of minimal residual diseas...
Albert Einstein College of Medicine

Managing Severe Asthma in the Era of Biologics: Early-Onset Asthma

In recent years, better understanding of asthma pathophysiology has led to the development of targeted biologics that have improved outcomes for some patients with severe asthma, and the Global Initiative for Asthma (GINA) guidelines now include biologics as a part of its stepwise treatment guidelines for personalized therapy. However, physicians continue to face challenges in determining when t...
University of Cincinnati and RedMedEd

Managing Severe Asthma in the Era of Biologics: Severe Persistent Eosinophilic Asthma

Although only a minority of asthma patients present with severe disease, these patients represent the greatest area of unmet clinical need in asthma care. A better understanding of asthma pathophysiology has resulted in the development of new targeted biologics in recent years, and this has improved outcomes for some patients with severe asthma and prompted the Global Initiative for Asthma (GINA...
University of Cincinnati and RedMedEd

MCL Patient Exam in the Era of Targeted Therapies: Workup, Prognosis, Treatment, and Monitoring

The rapid evolution of treatment advances in mantle cell lymphoma (MCL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of targeted agents in MCL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection, duration of treatment, management of treatment-related toxicities, and...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

Optimizing Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

The rapid evolution of treatment advances in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of targeted agents in MCL and CLL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection, duration of treatment, ...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

RME Hot Seat: Incorporating Personalized Treatment Into Severe Asthma Management

Severe, treatment-resistant asthma continues to be an extreme clinical challenge. An estimated 3%–10% of asthma patients have severe asthma, which is characterized by persistent symptoms, compromised lung function, and a significantly increased frequency and severity of high-risk outcomes. Fortunately, there have been important developments regarding the clinical management of patients with...
This CME-certified enduring activity is jointly provided by Rutgers Biomedical and Health Sciences and RedMedEd.

RME Hot Seat: Prognosis, Treatment Choice, and Risk Management for CLL and MCL

With the emergence of new targeted therapies and new prognostic indicators and goals of treatment, the clinical management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)—for patients in the frontline and relapsed/refractory settings—has evolved significantly. In this Q&A-based activity, our experts provide practical, evidence-based answers to questions relating to se...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

Shaping the Future of Myeloma Treatment

To help hematologist-oncologists keep pace with new advancements in multiple myeloma therapeutic regimens and management strategies, Shaping the Future of Myeloma Treatment features a roundtable discussion in which a panel of myeloma experts addresses a number of key clinical topics. Learners who participate in these activities will be expected to improve their ability to individualize treatment...
This CME-certified enduring activity is jointly provided by Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation.

Targeted Therapies in Severe Asthma: When to Use Them (and Why)

As the incidence of asthma—and the number of patients with severe, treatment-resistant asthma—continues to rise, the need for new management strategies has never been greater. Fortunately, several new tailored biologic therapies have recently been developed for certain patients with treatment-resistant severe asthma. The discovery that severe asthma comprises multiple phenotypes and discrete...
This CME-certified enduring activity is jointly provided by Rutgers Biomedical and Health Sciences and RedMedEd.

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.